| Added by | liaudet-coopman |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France] |
| Creator | Penault-Llorca et al. |
| Author | Frédérique Penault-Llorca |
| Author | Anne Vincent-Salomon |
| Author | Pascal Roger |
| Author | Isabelle Treilleux |
| Author | Alexander Valent |
| Author | Marie-Christine Mathieu |
| Author | Martine Antoine |
| Author | Catherine Bor |
| Author | Eva Brabencova |
| Author | Emmanuelle Charafe-Jauffret |
| Author | Marie-Pierre Chenard |
| Author | Marie-Mélanie Dauplat |
| Author | Paul Delrée |
| Author | Mojgan Devouassoux |
| Author | Maryse Fiche |
| Author | Marie-Eve Fondrevelle |
| Author | Viviana Fridman |
| Author | Christian Garbar |
| Author | Pascal Genin |
| Author | Jean-Pierre Ghnassia |
| Author | Juliette Haudebourg |
| Author | Sophie Laberge-Le Couteulx |
| Author | Delphine Loussouarn |
| Author | Aurélie Maran-Gonzalez |
| Author | Myriam Marcy |
| Author | Patrick Michenet |
| Author | Bruno Poulet |
| Author | Christine Sagan |
| Author | Martine Trassard |
| Author | Véronique Verriele |
| Author | Laurent Arnould |
| Author | Magali Lacroix-Triki |
| Abstract | International guidelines on HER2 determination in breast cancer have just been updated by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), on the basis of more than ten-year practice, results of clinical trials and concordance studies. The GEFPICS group, composed of expert pathologists in breast cancer, herein presents these recommendations, adapted to the French routine practice. These guidelines highlight the possible diagnosis difficulties with regards to HER2 status determination, such as intra-tumor heterogeneity, special histological subtypes and biomarker re-evaluation during metastatic relapse. Pre-analytical issues and updated scoring criteria (especially for equivocal cases) are detailed, in order to decrease the occurrence of false negative cases. In the era of personalized medicine, pathologists are more than ever involved in the quality of oncotheranostic biomarker evaluation. |
| Publication | Annales De Pathologie |
| Volume | 34 |
| Issue | 5 |
| Pages | 352-365 |
| Date | Oct 2014 |
| Journal Abbr | Ann Pathol |
| Language | fre |
| DOI | 10.1016/j.annpat.2014.08.018 |
| ISSN | 0242-6498 |
| Library Catalog | PubMed |
| Extra | PMID: 25439988 |
| Tags | Biomarkers, Tumor, Breast Neoplasms, Cancer du sein, clinic, False Negative Reactions, Female, France, Guidelines, HER2, Humans, Hybridation in situ, Immunohistochemistry, Immunohistochimie, In Situ Hybridization, In Situ Hybridization, Fluorescence, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prognosis, Receptor, ErbB-2, Recommandations |
| Date Added | 2019/05/29 - 13:16:28 |
| Date Modified | 2019/05/29 - 13:16:35 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
